Welcome to LookChem.com Sign In|Join Free

CAS

  • or

2587-03-3

Post Buying Request

2587-03-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2587-03-3 Usage

Description

2,6-Dichloro-4-nitraminopyridine, with the CAS number 2587-03-3, is a chemical compound that is characterized as a yellow solid. It is primarily recognized for its utility in the field of organic synthesis, where it serves as a valuable building block for the creation of various complex organic molecules.

Uses

Used in Organic Synthesis:
2,6-Dichloro-4-nitraminopyridine is used as a synthetic intermediate for the development of a wide range of organic compounds. Its unique chemical structure, featuring two chlorine atoms at the 2nd and 6th positions and a nitro group attached to the 4th position of the pyridine ring, makes it a versatile starting material for the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,6-Dichloro-4-nitraminopyridine is utilized as a key component in the synthesis of various drug candidates. Its reactivity and structural diversity allow for the creation of novel therapeutic agents with potential applications in treating a variety of medical conditions.
Used in Agrochemical Industry:
2,6-Dichloro-4-nitraminopyridine also finds application in the agrochemical industry, where it is employed in the development of new pesticides and other crop protection agents. Its chemical properties enable the design of innovative molecules with enhanced efficacy and selectivity, contributing to more effective and environmentally friendly agricultural practices.
Used in Dye and Pigment Industry:
The compound is also used as an intermediate in the synthesis of dyes and pigments, where its unique color properties and chemical stability contribute to the development of new and improved colorants for various applications, including textiles, plastics, and printing inks.

Check Digit Verification of cas no

The CAS Registry Mumber 2587-03-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,5,8 and 7 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2587-03:
(6*2)+(5*5)+(4*8)+(3*7)+(2*0)+(1*3)=93
93 % 10 = 3
So 2587-03-3 is a valid CAS Registry Number.
InChI:InChI=1/C5H4Cl2N3O2/c6-4-1-3(9-10(11)12)2-5(7)8-4/h1-2H,(H,8,9)(H,11,12)/q+1

2587-03-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,6-Dichloro-4-nitraminopyridine

1.2 Other means of identification

Product number -
Other names N-(2,6-dichloropyridin-4-yl)nitramide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2587-03-3 SDS

2587-03-3Relevant articles and documents

Discovery of MK-4688: An Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction

Altman, Michael D.,Bogen, Stephane,Cai, Mingmei,Cammarano, Carolyn,Chen, Dapeng,Christopher, Matthew,Cryan, John,Daublain, Pierre,Dussault, Isabelle,Fradera, Xavier,Geda, Prasanthi,Goldenblatt, Peter,Hill, Armetta D.,Kemper, Raymond A.,Kutilek, Victoria,Li, Chaomin,Machacek, Michelle R.,Marshall, C. Gary,Martinez, Michelle,McCoy, Mark,Nair, Latha,Pan, Weidong,Reutershan, Michael H.,Scapin, Giovanna,Shizuka, Manami,Spatz, Marianne L.,Steinhuebel, Dietrich,Sun, Binyuan,Thompson, Christopher F.,Trotter, B. Wesley,Voss, Matthew E.,Wang, Xiao,Yang, Liping,Yeh, Tammie C.

, p. 16213 - 16241 (2021/11/16)

Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein-protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward this goal. Adding to recent success in this area, we describe herein our efforts to optimize a novel purine carboxylic acid-derived inhibitor of the HDM2-p53 PPI into a series of low-projected dose inhibitors with overall favorable pharmacokinetic and physical properties. Ultimately, a strategy focused on leveraging known binding hot spots coupled with biostructural information to guide the design of conformationally constrained analogs and a focus on efficiency metrics led to the discovery of MK-4688 (compound 56), a highly potent, selective, and low-molecular-weight inhibitor suitable for clinical investigation.

Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors

Barsanti, Paul A.,Pan, Yue,Lu, Yipin,Jain, Rama,Cox, Matthew,Aversa, Robert J.,Dillon, Michael P.,Elling, Robert,Hu, Cheng,Jin, Xianming,Knapp, Mark,Lan, Jiong,Ramurthy, Savithri,Rudewicz, Patrick,Setti, Lina,Subramanian, Sharadha,Mathur, Michelle,Taricani, Lorena,Thomas, George,Xiao, Linda,Yue, Qin

supporting information, p. 42 - 46 (2015/01/30)

Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causative mechanisms for the observed PK. The series also harbored the CYP3A4 TDI liability driven by the presence of both a morpholine and an indole moiety. Incorporation of an adjacent fluorine or nitrogen into the 6-azaindole addressed many of the various medicinal chemistry issues encountered. (Chemical Presented).

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

-

Paragraph 0143; 0144, (2014/05/08)

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2587-03-3